PF-184563 is a potent selective non-peptidic antagonist of the V1a receptor. The compound was discovered by Pfizer in its Sandwich Kent research center as a potential treatment for dysmenorrhoea an indication for which V1a antagonists have shown efficacy.
This page contains content from the copyrighted Wikipedia article "PF-184563"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
